• 1. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 4. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

6-Bromo-4-chloroquinazolin-2-amine (CAS No. 1260862-26-7): A Versatile Building Block in Medicinal Chemistry

The 6-Bromo-4-chloroquinazolin-2-amine (CAS 1260862-26-7) represents an important quinazoline derivative that has gained significant attention in pharmaceutical research and drug discovery. This heterocyclic compound, with its unique bromine and chlorine substitutions, serves as a valuable scaffold for the development of various biologically active molecules. The molecular formula C₈H₅BrClN₃ and molecular weight of 258.50 g/mol make it an ideal intermediate for structure-activity relationship studies.

Recent trends in medicinal chemistry highlight the growing importance of halogenated quinazoline compounds in targeted drug design. The 6-bromo-4-chloro substitution pattern in particular has shown remarkable potential in kinase inhibition, making 6-Bromo-4-chloroquinazolin-2-amine a sought-after building block for cancer research applications. Its structural features allow for diverse modifications at multiple positions, enabling medicinal chemists to explore various pharmacophore configurations.

The synthesis of 6-Bromo-4-chloroquinazolin-2-amine typically involves multi-step organic transformations starting from commercially available precursors. Modern synthetic approaches emphasize green chemistry principles, with researchers developing more efficient and environmentally friendly routes to this valuable intermediate. Analytical characterization by HPLC, NMR, and mass spectrometry confirms the high purity (>98%) typically required for pharmaceutical applications.

In drug discovery pipelines, quinazoline-based compounds have demonstrated remarkable therapeutic potential across multiple disease areas. The 6-Bromo-4-chloroquinazolin-2-amine scaffold serves as a foundation for developing selective kinase inhibitors, particularly those targeting EGFR (Epidermal Growth Factor Receptor) family members. This aligns with current research priorities in precision medicine and personalized cancer therapies.

Beyond oncology applications, derivatives of 6-Bromo-4-chloroquinazolin-2-amine have shown promise in neurological disorders and inflammatory conditions. The compound's ability to serve as a precursor for various small molecule modulators makes it valuable for high-throughput screening programs and fragment-based drug design. Recent publications highlight its utility in developing novel antimicrobial agents as well.

The physicochemical properties of 6-Bromo-4-chloroquinazolin-2-amine contribute to its pharmaceutical relevance. With moderate lipophilicity (calculated LogP ~2.5) and good stability under physiological conditions, this compound offers favorable characteristics for lead optimization. Researchers frequently modify the 2-amino group or the halogen substituents to fine-tune drug-like properties during medicinal chemistry campaigns.

Market analysis indicates growing demand for high-quality 6-Bromo-4-chloroquinazolin-2-amine among contract research organizations and academic laboratories. Suppliers now offer this compound in various quantities, from milligram-scale for initial screening to kilogram quantities for preclinical development. The compound's CAS registry number (1260862-26-7) serves as a unique identifier in global chemical databases and procurement systems.

Recent advances in synthetic methodology have improved access to 6-Bromo-4-chloroquinazolin-2-amine and its derivatives. Catalytic approaches and flow chemistry techniques have reduced production costs while maintaining excellent purity standards. These developments support the compound's expanding role in fragment-based drug discovery and combinatorial chemistry applications.

Quality control protocols for 6-Bromo-4-chloroquinazolin-2-amine typically include rigorous analytical verification. Modern laboratories employ advanced techniques such as LC-MS and chiral HPLC to ensure batch-to-batch consistency, particularly important for structure-activity relationship studies. The compound's stability profile allows for long-term storage under appropriate conditions, making it practical for research programs.

The future outlook for 6-Bromo-4-chloroquinazolin-2-amine applications appears promising, with emerging research exploring its potential in targeted protein degradation (PROTACs) and covalent inhibitor design. Its versatile chemical structure continues to inspire innovative therapeutic approaches in both academic and industrial settings, solidifying its position as a valuable tool in modern drug discovery.

• 125096-72-2(8-Bromo-4-chloroquinazoline)
• 573675-55-5(7-Bromo-4-chloroquinazoline)
• 102393-82-8(6-Bromo-2,4-dichloroquinazoline)
• 351426-04-5(6-Bromo-4-chloro-2-methylquinazoline)
• 959237-68-4(7-bromo-2,4-dichloro-quinazoline)
• 38267-96-8(6-Bromo-4-chloroquinazoline)
• 885524-31-2(QUINAZOLINE, 6,7-DIBROMO-4-CHLORO-)
• 403850-84-0(7-Bromo-4-chloro-2-methylquinazoline)
• 2148-38-1(5-Bromo-4-chloro-quinazoline)
• 124309-74-6(4-Chloroquinazolin-2-amine)